Eupraxia Pharmaceuticals, Inc. EPRX 深 滬

美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级

今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元

06-29 15:49

Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17

Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.

06-26 21:12

Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%

05-26 18:00

美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价

今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元

05-22 10:18

Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25

Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.

05-21 18:06

Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over losses of $(0.21) per

05-13 05:08

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Eupraxia Pharmaceuticals Inc. reported positive clinical data and financial results for Q1 2026, highlighting significant progress in its EP-104GI treatment for Eosinophilic Esophagitis (EoE). The company completed a $63.2 million public offering to advance clinical trials and has sufficient cash reserves to fund operations into H2 2028. Recent highlights include near-complete tissue improvement in biopsy results and symptom data from the highest...

05-12 21:00

Eupraxia Reports Early Trial Results For EoE Drug, Doses Show Response In Mid-Stage Study

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,

05-05 19:15

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

05-01 21:05

美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价

今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元

04-23 12:35